U.S. Food and Drug Administration Approves Bristol Myers Squibb’s Breyanzi, a New CAR T Cell Therapy for Adults with Relapsed or Refractory Large B-cell Lymphoma
Bristol Myers Squibb, a member of Bio Nebraska, announced that the FDA has approved Breyanzi, a new CAR T therapy. Read more